EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links


[One point lesson 20200329] - End of document


[2020-3-27. Áú¹®] Ç×Ç÷¼ÒÆÇÁ¦

Ÿ°ú¿¡¼­ EGD/colono¸¦ ÀÇ·ÚÇÒ¶§ Ç×Ç÷ÀüÁ¦ Ç×Ç÷¼ÒÆÇÁ¦ º¹¿ë ÁßÀÌ´ø ȯÀÚ´Â (bleeding risk°¡ ¿Ã¶ó°£´Ù°í warningÀ» Çϸ鼭µµ) Á¶Á÷°Ë»ç´Â °¡´ÉÇϳª Å« ¿ëÁ¾ÀÇ CPP/EMRÀº ¾î·Æ´Ù°í ¹Ì¸® ȸ½ÅÀ» ÁÖ°í ÀÖ½À´Ï´Ù. À­³âÂ÷ ¼±»ý´Ôµé·ÎºÎÅÍ ¹ÞÀº ¿¹¹®¿¡¼­´Â aspirin 7ÀÏ Áß´Ü clopidogrel 5ÀÏ Áß´ÜÀ¸·Î ÀûÇôÀÖÀ¸³ª ȯÀÚ »óÅ¿¡ µû¶ó Á¶ÀýÇÒ ¼ö ÀÖµµ·Ï ȸ½Å ´äº¯À» °íÃƽÀ´Ï´Ù. CPP/EMR¿¡ ´ëÇØ Åë¿ëÇÒ ¼ö ÀÖ´Â Áß´Ü°¡´É ±â°£À» Á¤ÇÒ ¼ö ÀÖÀ»Áö ¹®Àǵ帳´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

°¡À̵å¶óÀÎÀ» ÁöÅ°´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù. AspirinÀ̳ª clopidogrelÀ» º¹¿ë ÁßÀΠȯÀÚÀÇ ³»½Ã°æ °Ë»ç, Á¶Á÷°Ë»ç¿¡¼­´Â ¾à¹° Áß´ÜÀÌ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù. ÀÌ °æ¿ì high risk procedure·Î »ý°¢µÇ´Â CPP³ª EMRÀº ÇÏÁö ¸øÇÒ °ÍÀÔ´Ï´Ù. ±×·¯³ª ¸ðµç ³»½Ã°æ °Ë»ç¿¡¼­ high risk polypectomy¸¦ one stage·Î ÇØ¾ß ÇÑ´Ù°í »ý°¢µÇÁö ¾Ê½À´Ï´Ù. Ȥ½Ã ¸ð¸¦ high risk polypectomy¸¦ À§ÇÏ¿© ¸ðµç ȯÀÚ¿¡¼­ aspirinÀ̳ª clopidogrelÀ» ³»½Ã°æ °Ë»ç Àü¿¡ Áß´ÜÇÑ´Ù¸é µæº¸´Ù ½ÇÀÌ ¸¹À» °¡´É¼ºÀÌ Å®´Ï´Ù. °¡À̵å¶óÀο¡¼­µµ À̸¦ ±ÇÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù. Áø´ÜÀº Áø´ÜÀÌ°í Ä¡·á´Â Ä¡·á¶ó´Â Á¡À» ¸íÈ®È÷ ±¸ºÐÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ƯÈ÷ aspirin/clopidogrel/warfarin/NOACÀ» º¹¿ëÇÏ´Â ºÐ¿¡¼­´Â ´õ¿í ±×·¯ÇÕ´Ï´Ù. °íÀ§Çè ȯÀÚ¿¡¼­ ¹«¸®ÇÏ¿© ½Ã¼úÇÏ´Ù°¡ »ç°í°¡ ³ª´Â ¹ýÀÔ´Ï´Ù. ¾à°£ÀÇ Æí¸®º¸´Ù ¾ÈÀüÀÌ ÈξÀ Áß¿äÇÑ °¡Ä¡ÀÔ´Ï´Ù.

CPP/EMR¿¡ ´ëÇؼ­´Â °¡À̵å¶óÀθ¶´Ù ¾à°£ÀÇ Â÷ÀÌ°¡ ÀÖ°í Àǻ簣ÀÇ °ßÇصµ »ó´çÈ÷ ´Þ¶ó¼­ ¿ì¸® º´¿ø¿¡¼­´Â ó¹æ°úÀÇ °áÁ¤À» µû¸£µµ·Ï ÇÏ°í ÀÖ½À´Ï´Ù. Consult¸¦ ³»°í ó¹æ°ú ÁöħÀ» µû¸£µµ·Ï ±ÇÇϽʽÿÀ.

À­³âÂ÷ ¼±»ý´Ôµé·ÎºÎÅÍ ¹ÞÀº ¿¹¹®¿¡ "aspirin 7ÀÏ Áß´Ü clopidogrel 5ÀÏ Áß´Ü"À¸·Î µÇ¾î ÀÖ´Â °ÍÀº ¸Õ ¿¾³¯ À̾߱âÀÔ´Ï´Ù. ±×·± Á·º¸´Â ´çÀå ¹ö¸®±â ¹Ù¶ø´Ï´Ù.

BSG/ESGE 2016 guideline

BSG/ESGE 2016 guideline

BSG/ESGE 2016 guideline

BSG/ESGE 2016 guideline


[2020-3-27. Áú¹®] Ç÷¼ÒÆÇ °¨¼ÒÁõ ȯÀÚ

Thrombocytopenia ȯÀÚ¿¡¼­ Á¶Á÷°Ë»ç °¡´ÉÀÇ ±âÁØÀÌ ÀÖ´ÂÁö ±Ã±ÝÇÕ´Ï´Ù. ÀÇ·Ú¸¦ ¹Þ¾Æ ³»½Ã°æ °Ë»ç¸¦ ÄÁÆßÀ» ÇÏ´Â ÀÔÀå¿¡¼­ ¼öÇ÷ ±âÁØÀÌ °í¹ÎÀÔ´Ï´Ù. ÁöÇ÷¼úÀ̸é 5¸¸ ÀÌ»ó ¸ÂÃç¼­ ÇÏÀÚ°í ¿¹¹®ÀÌ ³»·Á¿À±âµµ ÇÏ¿© ±×·¸°Ô ÇÏ°í´Â ÀÖ½À´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

Ç÷¼ÒÆÇÀÌ ³·Àº ȯÀÚÀÇ ³»½Ã°æ ¹× Á¶Á÷°Ë»ç ȤÀº polypectomy µîÀÇ ±âÁØÀº ¸íÈ®È÷ È®¸³µÇ¾î ÀÖÁö ¾Ê½À´Ï´Ù. °¡À̵å¶óÀÎÀº ÀÌ·¸½À´Ï´Ù.

WJG 2015

"Endoscopic Interventions in Patients with Thrombocytopenia"¶ó´Â ÀÎÅͺ並 º¸¸é MD Anderson Cancer CenterÀÇ Dr Ross´Â ´ÙÀ½°ú °°ÀÌ ¸»ÇÏ°í ÀÖ½À´Ï´Ù.

"We feel that the traditional threshold of 50,000 platelets/¥ìL that many doctors adhere to or aim for should be put aside, and a lower platelet threshold of perhaps 25,000/¥ìL or 30,000/¥ìL should be employed for endoscopic procedures, including biopsies."

2015³â ¸®ºä(Tong. WJG 2015)¿¡¼­´Â ¾Æ·¡¿Í °°ÀÌ ¾²°í ÀÖ½À´Ï´Ù. 5¸¸ ÀÌ»óÀ̸é ÁÁ°ÚÀ¸³ª ÀÓ»óÀûÀ¸·Î ÇÊ¿äÇÏ¸é ±×º¸´Ù ³·¾Æµµ ³»½Ã°æÀ» ½ÃÇàÇÏ°í 2¸¸ ÀÌ»óÀ̸é Á¶Á÷°Ë»çµµ ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀÔ´Ï´Ù.

"Most studies used a threshold of 50000/mm3 for prophylactic platelet transfusion prior to endoscopic procedures, although some performed uneventful endoscopies with lower counts. Therefore, based on this review and general practice guidelines, we recommend using 50000/mm3 as the threshold to performendoscopy. However, if clinically required, lower platelet counts may be considered by the endoscopist. Platelet transfusion during the procedure for patients who could not maintain this threshold is an option especially if a high risk procedure is planned. Although patients with lower platelet levels have undergone endoscopic procedures or endoscopic biopsies, duodenal biopsies, in particular, should be avoided if the platelet count is < 20000/mm3, as they can be a high risk factor for bleeding and hematoma development."

Ç÷¼ÒÆÇ °¨¼ÒÁõ ȯÀÚÀÇ ³»½Ã°æ °Ë»ç´Â ±× ¿øÀÎÀÌ Áß¿äÇÕ´Ï´Ù. Splenomegaly¿¡ ÀÇÇÑ Ç÷¼ÒÆÇ °¨¼ÒÁõÀº Å©°Ô ¹®Á¦µÇÁö ¾Ê½À´Ï´Ù. ´Ù¸¥ ÀÌÀ¯·Î Ç÷¼ÒÆÇ °¨¼ÒÁõÀÌ Àִ ȯÀÚ´Â ´ë°­ ¾Æ·¡¿Í °°ÀÌ ±ÇÇÕ´Ï´Ù. °³ÀÎÀû ±ÇÀ¯ÀÔ´Ï´Ù.

1) ³»½Ã°æ °Ë»çÀÇ ÀûÀÀÁõÀ» Àß »ìÆ캸°í ³»½Ã°æÀÌ ²À ÇÊ¿äÇÑ È¯ÀÚÀÎÁö È®ÀÎÇϽñ⠹ٶø´Ï´Ù. ³»½Ã°æ °Ë»ç¸¦ ÇÒ ¶§¿¡´Â clinically ²À Á¶Á÷°Ë»ç ÇÊ¿äÇÑÁö °í¹ÎÇØ¾ß ÇÕ´Ï´Ù. °Ç°­ÇÑ »ç¶÷ÀÇ °ËÁø ³»½Ã°æ°ú °°ÀÌ ÀÛ°í ¾Ö¸ÅÇÑ º´¼Ò¿¡¼­ Á¶Á÷°Ë»çÇÏ´Â ÀÏÀº °¡±ÞÀû ÇÇÇϱ⠹ٶø´Ï´Ù.

2) Ç÷¼ÒÆÇ 2¸¸ ÀÌ»óÀÌ¸é ´ëºÎºÐÀÇ ³»½Ã°æ °Ë»ç´Â ½ÃÇàÇÒ ¼ö ÀÖ°í ÇÊ¿äÇϸé Á¶Á÷°Ë»çµµ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀûÀÎ Áø´Ü³»½Ã°æ Àü Ç÷¼ÒÆÇ ¼öÇ÷Àº Á¤¸»·Î ²À ÇÊ¿äÇÑ °æ¿ì¿¡¸¸ ¾ÆÁÖ Á¦ÇÑÀûÀ¸·Î °í·ÁÇϽñ⠹ٶø´Ï´Ù. ¿¹¸¦ µé¾î ¶Ñ·ÇÇÑ ¾ÏÀÌ ÀÖÀ¸¸é Ç÷¼ÒÆÇÀÌ 2-5¸¸ÀÌ´õ¶óµµ Á¶Á÷°Ë»ç¸¦ ÇÏ´Â °ÍÀÌ ³´½À´Ï´Ù.

3) Ç÷¼ÒÆÇ ¼öÇ÷ ÀÚüµµ ÀûÁö¾ÊÀº ºÎÀÛ¿ëÀÌ ÀÖÀ¸¸ç, ½ÇÁ¦·Î ¿©·¯¹ø ¼öÇ÷¹ÞÀº ȯÀÚÀÇ °æ¿ì Ç÷¼ÒÆÇ ¼öÇ÷À» ÇÏ´õ¶óµµ Ç÷¼ÒÆÇÀÌ Àß ¿Ã¶ó°¡Áö ¾Ê´Â ȯÀÚ°¡ ¸¹½À´Ï´Ù. ÀÓ»óÀû µæ°ú ½ÇÀ» °í·ÁÇØ¾ß ÇÕ´Ï´Ù.

4) Active bleedingÀÌ Àִ ȯÀÚ´Â Ç÷¼ÒÆÇÀ» 5¸¸ ÀÌ»ó À¯ÁöÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù.

5) Ç÷¼ÒÆÇ °¨¼ÒÁõ ȯÀÚ¿¡¼­ elective therapeutic endoscopy°¡ ÇÊ¿äÇϸé fellow ¼±»ý´Ô ¼öÁØ¿¡¼­ °áÁ¤ÇÏÁö ¸¶½Ã°í ±³¼ö´Ôµé²² consult ÇϽʽÿÀ.


[2020-3-27. Áú¹®] Hp follow up

À§±Ë¾çÀ̳ª post ESD ȯÀÚÀÇ f/u ³»½Ã°æ ½Ã Áö³­ °Ë»ç¿¡¼­ HP (+)·Î È®ÀεǾú°í ±×·¡¼­ Á¦±ÕÄ¡·á¸¦ ½ÃÇàÇÑ °æ¿ì¿¡ ¼ÒÈ­±â³»°ú ±³¼ö´Ô ¿Ü·¡¿¡¼­´Â ´ëºÎºÐ Urea Breath test ¸¦ ó¹æÀ» °°ÀÌ ÇϽôµ¥ ÀúÈñ°¡ ³»½Ã°æÀ» º¼ ¶§ HP f/u °Ë»ç¸¦ ÇÏ´Â °ÍÀÌ ¸Â´ÂÁö, °°Àº³¯ UBT test °¡ ó¹æÀÌ µÇ¾îÀÖ´Ù¸é ¾ÈÇÏ´Â °ÍÀÌ ¸ÂÀ»Áö ¿©Âã½À´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

Ç︮ÄÚ¹ÚÅÍ °ü·Ã À§±Ë¾ç ȤÀº ¼ÒÈ­¼º±Ë¾ç ȯÀÚ¿¡¼­´Â Hp Á¦±ÕÀÌ ¸Å¿ì Áß¿äÇϹǷΠºñ·Ï UBT°¡ ÀÖ´õ¶óµµ Hp Á¶Á÷°Ë»ç¸¦ ÇÏ´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.

¼ÒÈ­¼º ±Ë¾çÀÌ ¾Æ´Ñ ȯÀÚ¿¡¼­ ¼±º°±Þ¿© (100/100) Á¦±ÕÄ¡·á¸¦ ¹ÞÀº ȯÀÚ¿¡¼­´Â UBT¸é ÃæºÐÇÕ´Ï´Ù. Hp Á¶Á÷°Ë»ç±îÁö ÇÊ¿äÇÏÁö´Â ¾ÊÀ» °Í °°½À´Ï´Ù.

À§¾Ï ESD ȯÀÚ¿¡¼­´Â º¸Åë UBT¸é ÃæºÐÇÕ´Ï´Ù. UBT ó¹æÀÌ Àִµ¥ ±¸Å¿© Hp Á¶Á÷°Ë»ç±îÁö ÇÒ ÇÊ¿ä´Â ¾øÀ» °Í °°½À´Ï´Ù.


[2020-3-27 Áú¹®] À§±Ë¾ç ³»½Ã°æ Ä¡·á ÈÄ rebleeding risk

Gastric ulcer bleedingÀÇ °æ¿ì °ÅÀÇ Forrest IIa±îÁö´Â ÁöÇ÷¼úÀ» ÇÏ°í IIb´Â ÇÒÁö¸»Áö °áÁ¤ÇÏ´Â °ÍÀ¸·Î °øºÎÇߴµ¥ ½ÇÁ¦·Î ÀÔ¿øÇؼ­ °æ°ú°üÂûÇÏ¿© rebleedingÀ» °í·ÁÇØ¾ß ÇÏ´Â °ÍÀº ¾î¶² Á¤µµÀÏÁö ±Ã±ÝÇÕ´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

ÃÖ±Ù¿¡´Â ÁöÇ÷¼úÀÌ Àß µÇ¾úÀ¸¸é rebleedingÀ» °í·ÁÇÏ¿© second look endoscopy (SLE)¸¦ °èȹÇÒ ÇÊ¿ä´Â ¾ø½À´Ï´Ù.

ÀçÃâÇ÷ À§ÇèÀº Forrest ºÐ·ùµµ Áß¿äÇÏÁö¸¸, ÀÓ»óÀûÀ¸·Î´Â ù presentation½Ã vital signÀÌ Áß¿äÇÕ´Ï´Ù. ShockÀ¸·Î ³»¿øÇÑ È¯ÀÚ, hematemesis·Î ³»¿øÇÑ È¯ÀÚ, °í·É, ´ÙÀå±â ÁúȯÀ» °¡Áø ȯÀÚ ¿Í °°Àº ÀÓ»óÀû risk factor°¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.


[2020-3-27 Áú¹®] Hyperplastic polyp

ASGE °¡À̵å¶óÀÎ (2006)¿¡¼­´Â >0.5cmÀ̸é polypectomy¸¦ ±Ç°íÇÏ°í, 2016³â ´ëÇÑ ³»°úÇÐȸÁö¿¡¼­´Â 1cm ÀÌ»óÀÎ °æ¿ì polypectomy¸¦ ±Ç°íÇÏ°í, ¼­±¸¿¡¼­´Â Hp¸¦ ±ÇÀåÇÏÁö¸¸ ÇöÀç ±¹³»ÀÇ °¡À̵å¶óÀο¡¼­´Â Æ÷ÇԵǾî ÀÖÁö ¾ÊÀº »óÅÂÀÓÀ» ¾ð±ÞÇÏ°í ÀÖ½À´Ï´Ù. Uptodate¿¡¼­´Â hyperplastic poypÀÌ ÀÖ´Â °æ¿ì¿¡¼­ Hp°¡ È®ÀÎµÈ °æ¿ì Á¦±ÕÄ¡·á¸¦ ½ÃÇàÇÏ´Â °ÍÀ» ±Ç°íÇÏ°í ÀÖ½À´Ï´Ù. ÀÛ³â ÀúÈñ ±¹½Ã ¿¬¼ö°­Á¿¡¼­´Â hyperplastic polypÀÌ È®ÀÎµÈ °æ¿ì Hp ¾ç¼ºÀÎ °æ¿ì Á¦±ÕÄ¡·áÇÏ°í 1cm ÀÌ»ó or pedunculated polypÀº polypectomy¸¦ ÇÏ°í, ÇØ´çµÇÁö ¾ÊÀº °æ¿ì surveillance¸¦ ÇÏ´Â ¹æ¹ýÀÌ Á¦½ÃµÇ¾ú½À´Ï´Ù. ±³¼ö´Ô²²¼­´Â ¾î¶»°Ô managementÇϽðí follow upÇϽôÂÁö ±Ã±ÝÇÕ´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

¾Æ·¡¿Í °°ÀÌ ¼³¸íÇÏ°í ÀÖ½À´Ï´Ù (EndoTODAY ¿Ü·¡ ¼³¸í¼­ - ¿ëÁ¾).

"ºñ¼±Á¾¼º (ÞªàÍðþàõ) ¿ëÁ¾Àº ¾ÏÀ¸·Î ¹ßÀüÇÒ °¡´É¼ºÀÌ ³·±â ¶§¹®¿¡ ÀÛÀ¸¸é Ä¡·áÇÏÁö ¾Ê°í 1-2 cm ÀÌ»óÀÏ ¶§ ÀýÁ¦¼úÀ» ±ÇÇÕ´Ï´Ù. ºñ¼±Á¾¼º ¿ëÁ¾Àº ´Ù¹ß¼ºÀÌ Æ¯Â¡À̹ǷΠġ·á ÈÄ Àç¹ßÀº ÈçÇÑ ÆíÀÔ´Ï´Ù. ´ÙÇàÈ÷ Àç¹ß·Î ÀÎÇÏ¿© ¿©·¯¹ø Ä¡·á¸¦ ¹Þ´Â ºÐÀº ¸¹Áö ¾Ê½À´Ï´Ù. ÀÛÀº ¿ëÁ¾Àº Àç¹ßÇÏ´õ¶óµµ Ä¡·áÇÏÁö ¾Ê±â ¶§¹®ÀÔ´Ï´Ù.

ÃÖ±Ù °ËÁø µî¿¡¼­ ±âº» °Ë»ç¸¦ ¹Þ°í Å« ÀÌ»óÀÌ ¾øÀ¸¼Ì´Ù¸é Ãß°¡ °Ë»ç ¾øÀÌ ¹Ù·Î ½Ã¼úÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëºÎºÐ ÀÔ¿øÇÏÁö ¾Ê°í ¿Ü·¡ ³»½Ã°æ½Ç¿¡¼­ ½Ã¼úÇÕ´Ï´Ù.

³»½Ã°æ ½Ã¼ú ÈÄ 30ºÐ Á¤µµ ȸº¹½Ç¿¡¼­ ¾ÈÁ¤À» ÃëÇÑ ÈÄ Åð½ÇÇÏ°Ô µË´Ï´Ù. ½Ã¼ú 2½Ã°£ ÈÄ (= Åð½Ç 1½Ã°£ ÈÄ) ¹°À̳ª À½·á¼ö(¿ìÀ¯, µÎÀ¯µµ °¡´É)¸¦ ¸¶½Ã°í, ½Ã¼ú 3½Ã°£ ÈÄ (= Åð½Ç 2½Ã°£ ÈÄ) ºÎµå·¯¿î Á×À» µå½Ê½Ã¿À. ´ÙÀ½ ³¯ ¾ÆħÀº ¹äÀ» µå¼Åµµ ÁÁ½À´Ï´Ù¸¸ ´Ü´ÜÇÑ ¹ÝÂùÀº ÇÇÇϽʽÿÀ. ¾àÀº 2ÁÖ°£ ÇÏ·ç ÇÑ ¾Ë ¾Æħ ½ÄÀü¿¡ º¹¿ëÇϽʽÿÀ. ±Í°¡ ÈÄ ÃâÇ÷À§ÇèÀÌ ÀÖ½À´Ï´Ù¸¸, ±× ºóµµ´Â 2% Á¤µµÀÔ´Ï´Ù. ±× °æ¿ì ¿¬¶ôÀ» Áֽðųª º´¿øÀ» ã¾ÆÁֽʽÿÀ. ¸çÄ¥°£ ¾à°£ ¾ÆÇà ¼ö ÀÖ½À´Ï´Ù. ÁøÁ¤(¼ö¸é)³»½Ã°æ ÈÄ ´çÀÏÀº Àý´ë ¿îÀüÇÏÁö ¸¶½Ã°í, º¸È£ÀÚ¿Í ÇÔ²² ±Í°¡ÇϽñ⠹ٶø´Ï´Ù.

ÃÖÁ¾ º´¸®°á°ú´Â ¿Ü·¡¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù."


[2020-3-27 Áú¹®] SMT workup

¿Ü·¡¸¦ º¸´Ùº¸¸é Ÿ¿ø¿¡¼­ È®ÀÎµÈ SMT·Î ÃÊÀ½ÆÄ ³»½Ã°æÀÌ ÇÊ¿äÇÏ´Ù´Â ¾ê±â¸¦ µè°í ¿À½Ã´Â ºÐµéÀÌ Á¾Á¾ °è½Ê´Ï´Ù. ±³¼ö´ÔÀÌ º¸³»ÁֽŠ¼­¿ï´ëº´¿ø °­³²¼¾ÅÍ ÀÚ·á¿¡ µû¸£¸é 2cm ³Ñ´Â °æ¿ì EUS¸¦ ±ÇÀ¯Çß´Ù°í Çϴµ¥, Áø·á¿¡ À־ 2cm ÀÌÇϽà °æ°ú °üÂûÇÏ°í ÀÌ»óÀ̶ó¸é EUS ´ë½Å CT·Î È®ÀÎ ÈÄ ÀϹݿܷ¡¿¡¼­ 3cm Àü±îÁö ³»½Ã°æÀ¸·Î ÃßÀû°üÂûÇصµ µÉÁö »óÀǵ帳´Ï´Ù

[2020-3-28. ÀÌÁØÇà ´äº¯]

ÀÏ´Ü È¯ÀÚÀÇ Áõ»óÀ» »ìÇǽʽÿÀ. º¹ÅëÀ¸·Î ³»½Ã°æ °Ë»ç¸¦ Çߴµ¥ 1cm SMT¶ó´Â ¼Ò°ß¼­¸¦ °¡Áö°í ¿À´Â ºÐµéÀÌ °è½Ê´Ï´Ù. »ç½ÇÀº °£Áúȯ, ÃéÀå¾Ï, ´ëÀå¾Ï µîÀÌ ¿øÀÎÀε¥ ¸»Àä... SMT´Â Áõ»óÀÇ ¿øÀÎÀÌ ¾Æ´Ï¹Ç·Î ºñ·Ï SMT·Î ÀǷڵǾú´õ¶óµµ Áõ»óÀÌ ÀÖ´Â ºÐÀº ±×¿¡ ´ëÇÑ °Ë»ç¸¦ ÇϽñ⠹ٶø´Ï´Ù.

¹«Áõ»ó ¼ºÀÎÀÇ SMT¿¡¼­ Àú´Â stomach CT¸¦ ÁÖ·Î ÀÌ¿ëÇÏ°í ÀÖ½À´Ï´Ù. °¡Àå °´°üÀûÀ̱⠶§¹®ÀÔ´Ï´Ù. º¸ÅëÀÇ ±âÁØÀº 1cm·Î »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. EUSµµ °¡´ÉÇÏÁö¸¸, ´ëÇüº´¿ø¿¡¼­´Â ¿©·¯ºÐÀÌ EUS¸¦ Çϱ⠶§¹®¿¡ interobserver variation ¹®Á¦°¡ À־ ÀÚÁÖ ½ÃÇàÇÏÁö ¾Ê½À´Ï´Ù. º»ÀÎÀÌ EUSµµ ÇÏ°í ¿Ü·¡ ÃßÀû°üÂûÀ» ÇÒ ¼ö ÀÖ´Â »óȲ¿¡¼­´Â EUS¸¦ ¼±ÅÃÇÏ½Ã°í ±×·¸Áö ¾ÊÀº »óȲ¿¡¼­´Â CT¸¦ ¼±ÅÃÇÏ´Â °ÍÀÌ ´õ ¾ÈÀüÇÒ °Í °°½À´Ï´Ù.


[2020-3-27 Áú¹®] MALToma

10°³¿ù Àü MALToma, stage IE1, H. pylori (+)·Î Á¦±ÕÄ¡·á ÈÄ 4°³¿ù ÃßÀû°Ë»ç¿¡¼­ rRD, 10°³¿ù ÃßÀû°Ë»ç¿¡¼­ MALToma·Î ³ª¿Â ºÐÀÔ´Ï´Ù. ³»½Ã°æ À°¾ÈÀº nodular, hyperemic discolorationÀ¸·Î 3¹øÀÇ ³»½Ã°æ µ¿¾È º¯È­´Â ¾ø¾ú½À´Ï´Ù. ÀÌ·² °æ¿ì watch and wait ¸¦ Çغ¼ ¼ö ÀÖÀ» °Í °°Àºµ¥, f/u EGD ¹× CT µîÀÇ Ãß°¡ °Ë»ç °£°ÝÀ» ¾î¶»°Ô ÇϽôÂÁö, fusion gene °Ë»çµµ °í·ÁÇϽôÂÁö ±Ã±ÝÇÕ´Ï´Ù.

[2020-3-29. ÀÌÁØÇà ´äº¯]

Çö´ë ÀÇ·á¿¡¼­ °³ÀÎÀÇ »ý°¢Àº ¾î¶°ÇÑ Àǹ̰¡ ÀÖÀ»±î¿ä? °¡À̵å¶óÀο¡ µû¸£Áö ¾Ê°í Àڱ⠻ý°¢´ë·Î Ä¡·áÇÏ´Â °ÍÀÌ ¹Þ¾Æµé¿©Áú ¼ö ÀÖÀ»±î¿ä? ´ëºÎºÐ ¾Æ´Ò °ÍÀÔ´Ï´Ù. °¡À̵å¶óÀÎÀ̳ª textbook ȤÀº consensus¿¡ µû¸¥ Ä¡·á°¡ ÃÖ¼±ÀÔ´Ï´Ù.

°¡À̵å¶óÀÎÀ̳ª textbook ȤÀº consensusÀÇ ³»¿ëÀÌ °³ÀÎÀÇ °æÇè°ú ÀÏÄ¡ÇÏÁö ¾ÊÀ¸¸é ¾î¶»°Ô ÇØ¾ß ÇÒ±î¿ä? ƯÈ÷ ±× °³ÀÎÀÌ ¾î¼´Ù Çѹø ±× º´À» Ä¡·áÇÏ´Â »ç¶÷ÀÌ ¾Æ´Ï°í ´Ã ±× Áúº´À» Ä¡·áÇÏ´Â, ¾î¼¸é °¡Àå ¸¹ÀÌ Ä¡·áÇÏ´Â »ç¶÷ÀÎ °æ¿ì¿¡ ±× °³ÀÎÀÇ ÀÇ°ß¿¡ ¾î¶² Àǹ̸¦ ºÎ¿©ÇÒ ¼ö ÀÖÀ»±î¿ä?

ÀúÀÇ Áø·á½Ç¿¡¼­ Á¦ »ý°¢´ë·Î Ä¡·áÇÏÁö ¸øÇÏ´Â 3°¡Áö ¿µ¿ªÀÌ ÀÖ½À´Ï´Ù. (1) ÃÊ°í·ÉÀÚ, (2) MALToma, (3) HelicobacterÀÔ´Ï´Ù. Á¦ °æÇèÀ̳ª »ý°¢°ú °¡À̵å¶óÀÎÀÌ ³Ê¹«³ª ´Ù¸£±â ¶§¹®ÀÔ´Ï´Ù. ±× °á°ú ÀÌ ºÎºÐÀÇ Á¦ Áø·á´Â ¾îÁ¤ÂÄ ±× ÀÚüÀÔ´Ï´Ù.

* Âü°í: EndoTODAY MALToma Á¦°¡ À̹ø´Þ ÀϹÝÇùÁø ´ã´çÀ¸·Î Ÿ°úÀÇ ³»½Ã°æ ÇùÁøÀ» ÄÁÆßÇÏ´Ùº¸´Ï °í¹ÎÀÌ µÇ´ø °ÍµéÀÌ ÀÖ½À´Ï´Ù.


[2020-3-27 Áú¹®] Duodenal ampulla

±³¼ö´Ô duodenum¿¡¼­´Â size¸¦ ¾î¶»°Ô measureÇϽôÂÁö ±Ã±ÝÇÕ´Ï´Ù. DEX¿¡¼­ À§´Â 6cm·Î ¹è¿ü´Âµ¥ ½ÊÀÌÀÌÀåÀº ¾î¶»°Ô ÇÏ´Â °ÍÀÌ ÁÁÀ»±î¿ä?

Prominent AoVÀÇ Á¤ÀÇ´Â, ´ëºÎºÐ AoV°¡ ½ÊÀÌÁöÀå ³»°­À¸·Î 1cm ÀÌÇÏ·Î µ¹ÃâµÇ¾î Àִµ¥ µ¹ÃâÀÌ ±× ÀÌ»óÀ¸·Î ½ÉÇÑ °æ¿ì ȤÀº openingÀÇ papillaÀÇ À°¾ÈÀû º¯È­ ¼Ò°ßÀ» ¹ÙÅÁÀ¸·Î ÆÇ´ÜÇÏ´Â °ÍÀ¸·Î »ý°¢ÇÏ°í ÀÖ¾ú½À´Ï´Ù. Á¦°¡ ÃÖ±Ù ³»½Ã°æÇϸ鼭 prominent AoV¿¡ ´ëÇØ °Ë»ç ÀÇ·ÚµÇ¾î ¿Â ¿Ü·¡ ȯÀÚ°¡ ÀÖ¾ú½À´Ï´Ù. AoV °Ë»ç ¸ñÀûÀ¸·Î ERCPÆÀÀÌ ¾Æ´Ñ ³»½Ã°æ½Ç·Î ¿À´Â °ÍÀº ±¦ÂúÀºÁö¿¡ ´ëÇؼ­µµ °°ÀÌ »ý°¢ÇØ º¸¸é ÁÁÀ» °Í °°½À´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

½ÊÀÌÁöÀå ±¸ºÎ´Â ³»°­ÀÌ 3cm¶ó°í »ý°¢ÇÏ°í ÀÖ½À´Ï´Ù. Á¦2ºÎ´Â 2.5cm Á¤µµÀÔ´Ï´Ù.

Prominent AoV´Â ERCP ÆÀ¿¡¼­ workupÇÏ´Â °ÍÀÌ ´õ ÁÁ½À´Ï´Ù. ÀÇ·ÚÇϼŵµ ÁÁ½À´Ï´Ù.


[2020-3-27 Áú¹®] Divereticular bleeding ÈÄ ÀÔ¿ø ±âÁØ

¶È°°Àº Diverticular bleedingÀÌ°í clippingÀ» Çصµ ¾î¶² ºÐÀº ÀÔ¿ø, ¾î¶² ºÐÀº Åð½ÇÇÏ°Ô µÇ´Âµ¥ ¸íÈ®ÇÑ ÆÇ´ÜÀÌ Àß ¼­Áö ¾Ê½À´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

¿ì¸®³ª¶ó¿¡¼­´Â ³»½Ã°æ ÁöÇ÷¼ú ÈÄ ÁýÀ¸·Î ¹Ù·Î º¸³»´Â °æ¿ì´Â º°·Î ¾ø½À´Ï´Ù. 1-2ÀÏ Á¤µµ ÀÔ¿ø ÈÄ Åð¿øÇÏ´Â °ÍÀÌ ¾ÈÀüÇÕ´Ï´Ù. ´Ù¸¸ ù presentation ½Ã shockÀÌ ¾ø¾ú°í, ´ÙÀå±â ÁúȯÀÌ ¾ø´Â ȯÀÚ¿¡¼­ ³»½Ã°æ ÁöÇ÷¼úÀÌ Àß µÇ¾úÀ¸¸é ÀÔ¿øÇÏÁö ¾Ê°í ÀÀ±Þ½Ç¿¡¼­ Åð½ÇÀ» °í·ÁÇÒ ¼ö ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù.


[2020-3-27 Áú¹®] Á¶Á÷°Ë»ç pending

Á¶Á÷°Ë»ç È®ÀÎÀ» ÇÏ´Ùº¸¸é ´Ù¸¥ °Ë»çº¸´Ù Á¶±Ý ´Ê°Ô ³ª¿À¸é¼­ pending deeper cut ¶ó´Â ¹®±¸¸¦ º¸°Ô µË´Ï´Ù. º´¸®ÇÐÀû Àǹ̶ó ã±â ¾î·Á¿ö Ȥ½Ã ¾î¶² ÀǹÌÀÎÁö Áú¹®µå¸³´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

PendingÀº ¾ÆÁ÷ °á°ú°¡ ³ª¿ÀÁö ¾Ê¾Ò´Ù´Â ÀǹÌÀÔ´Ï´Ù. º´¸®°ú Àǻ簡 H&E °Ë»ç¸¸À¸·Î °á·ÐÀ» ³»±â ¾î·Á¿ö ¼­·Î ÇùÀÇ ÁßÀ̰ųª immunohistochemistry¸¦ ½ÃÇàÇÏ°í ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.


[2020-3-27. Áú¹®] NG tube

À̹ø ´Þ¿¡´Â NJ tube insertion ÇùÁøÀÌ ¸¹Áö ¾Ê¾Ò½À´Ï´Ù. Sarcoma mass exciscion, Rt. hemicolectomy, small bowel obstruction ¼ö¼ú µî ¹ÞÀº ȯÀÚ¿¡¼­ EGD·Î tube¸¦ pylrous·Î ³Ñ°Ü´Þ¶ó´Â ¿äûÀÌ ¿Â ÀûÀÌ ÀÖ½À´Ï´Ù. °è¼Ó ¹Ýº¹ÀûÀ¸·Î ºüÁú °ÍÀ̶ó´Â Á¡¿¡¼­ Àú´Â ȸÀÇÀûÀ̾úÀ¸³ª È¿°ú°¡ ¾øÀ¸´Ï ÇÏÁö¾Ê´Â °ÍÀÌ ÁÁ°Ú´Ù°í ´ÜÁ¤Çϴ ȸ½ÅÀ» Çϱ⵵ ¾î·Á¿ü½À´Ï´Ù.

[2020-3-28. ÀÌÁØÇà ´äº¯]

Àú´Â NJ tubeÀÇ È¿°ú¸¦ ±×´ÙÁö ½Å·ÚÇÏÁö ¾Ê½À´Ï´Ù. ±Ý¹æ ºüÁö´Â °æ¿ì°¡ ´ëºÎºÐÀ̾ú½À´Ï´Ù. ªÀº Àӻ󿬱¸¸¦ Çغ¸¸é ÁÁÀ» °Í °°½À´Ï´Ù.


[2020-3-27 Áú¹®] PRG

PRG change ȯÀÚÀε¥ guidewire°¡ ´ê¾Ò´ÂÁö antrum LC¿¡ holeÀÌ »ý°Ü¼­ active bleedingÀ» º¸¿© clippingÀ» Çß½À´Ï´Ù. PRG change ÈÄ ±Í°¡ÇÏ¿´´Âµ¥ 3ÀÏ°£ melena¸¦ ¹öƼ´Ù°¡ ¿À½Å ºÐµµ ÀÖ¾ú½À´Ï´Ù.


¼ÒÅëÇÏ´Â ³»½Ã°æ


[References]

1) EndoTODAY One point lesson

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. (since 1999-8-23)